LY 178002 |
| カタログ番号GC30610 |
LY 178002 は、5-リポキシゲナーゼ (5-LPO)、ホスホリパーゼ A2 の強力な阻害剤であり、5-リポキシゲナーゼの IC50 は 0.6 μM であり、ヒト多形核白血球による LTB4 の細胞産生を阻害し、シクロオキシゲナーゼに対して比較的弱い阻害を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 107889-32-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LY 178002 is a potent inhibitor of 5-lipoxygenase, phospholipase A2, with IC50 of 0.6 μM for 5-1ipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
LY178002 inhibits the generation of LTB4, PLA2 and FCO with IC50s of 0.1, 6.3 and 4.2 μM [1].
LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81%, and inhibits bone damage in rats. The minimum effective dose for LY178002 is 10 mg/kg p.o. In the established FCA model LY178002 at 50 mg/kg p.o. inhibits the uninjected paw swelling by 75%[1].
[1]. Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *